

Haifa Kathrin Al-ali

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4421/haifa-kathrin-al-ali-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

109
papers

3,883
citations

23
h-index

62
g-index

112
ext. papers

4,516
ext. citations

3.6
avg, IF

4.53
L-index

#	Paper	IF	Citations
109	Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning-Eudract #: 2007-002420-15.. <i>Bone Marrow Transplantation</i> , 2022 ,	4.4	
108	Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. <i>Leukemia</i> , 2021 , 35, 3455-3465	10.7	10
107	Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study. <i>Hematological Oncology</i> , 2021 , 39, 558-566	1.3	4
106	Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study. <i>Leukemia and Lymphoma</i> , 2021 , 62, 918-926	1.9	9
105	Altered Spatial Composition of the Immune Cell Repertoire in Association to CD34 Blasts in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia. <i>Cancers</i> , 2021 , 13,	6.6	3
104	Clinical Discernment, Bone Marrow, and Molecular Diagnostics Are Equally Important to Solve the Phenotypic Mimicry among Subtypes of Myeloproliferative Neoplasms. <i>Reports</i> , 2021 , 4, 27	0.4	
103	Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. <i>British Journal of Haematology</i> , 2020 , 189, 888-903	4.5	29
102	Phenotypes of JAK2-Mutated Polycythemia Vera and Essential Thrombocythemia with and without Thromboembolic Events: Results of the Hinc-207 (OSHO #91) Study. <i>Blood</i> , 2020 , 136, 13-13	2.2	
101	The Incidence of Mastocytosis in Patients with Unclear Cytopenia and/or Leucocytosis: The Hryd Study. <i>Blood</i> , 2020 , 136, 17-18	2.2	
100	Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	6
99	No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2821-2830	1.9	
98	Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis. <i>Genes Chromosomes and Cancer</i> , 2019 , 58, 747-755	5	5
97	Aggressive systemic mastocytosis: a diagnostic challenge in a patient with myotonic dystrophy type 2: a case report. <i>Annals of Hematology</i> , 2019 , 98, 2825-2827	3	1
96	An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor. <i>Blood</i> , 2019 , 134, 2945-2945	2.2	6
95	Impact of Somatic Mutations on Outcome in Patients > 60 Years Old with Newly Diagnosed AML Treated with Response-Adapted Sequential Azacitidine and Induction Chemotherapy within the DRKS00004519 Trial (RAS-AZIC) of the East German Study Group of Hematology and Oncology (OSHO). <i>Blood</i> , 2019 , 134, 1429-1429	2.2	
94	Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome. <i>Blood</i> , 2019 , 134, 2952-2952	2.2	
93	Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies. <i>Blood</i> , 2019 , 134, 1358-1358	2.2	

92	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019 , 7, 81-87	5.4	24
91	Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in Myeloproliferative Neoplasms (MPN) - Data from the Bioregistry of the German Study Group for MPN (GSG-MPN). <i>Blood</i> , 2018 , 132, 4292-4292	2.2	
90	Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients > 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO). <i>Blood</i> , 2018 , 132, 83-83	2.2	1
89	Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. <i>Leukemia</i> , 2018 , 32, 2546-2557	10.7	62
88	Managing patients with myelofibrosis and low platelet counts. <i>Annals of Hematology</i> , 2017 , 96, 537-548	3	8
87	Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. <i>BMC Cancer</i> , 2017 , 17, 852	4.8	29
86	A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. <i>Leukemia</i> , 2017 , 31, 896-902	10.7	35
85	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	16
84	Primary mediastinal large B cell lymphoma: Frontline treatment with an alternating chemotherapy regimen based on high dose methotrexate - A single institution experience. <i>JMS - Journal of Medical Society</i> , 2017 , 31, 8	0.2	1
83	Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016 , 51, 89-95	4.4	27
82	Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. <i>Haematologica</i> , 2016 , 101, 1065-73	6.6	108
81	Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. <i>Leukemia</i> , 2016 , 30, 1701-7	10.7	273
80	Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 317-24	4.9	10
79	Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2464-7	1.9	22
78	Favorable outcome in children and adolescents with a high proportion of advanced phase disease using single/multiple autologous or matched/mismatched allogeneic stem cell transplantations. <i>Annals of Hematology</i> , 2016 , 95, 473-81	3	2
77	Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study. <i>Blood</i> , 2016 , 128, 1066-1066	2.2	4
76	Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR). <i>Blood</i> , 2016 , 128, 1638-1638	2.2	2
75	Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233). <i>Blood</i> , 2016 , 128, 3107-3107	2.2	3

74	Hematopoietic stem cell transplantation (HSCT) compared to consolidation chemotherapy (CT) to increase leukemia free survival (LFS) in acute myelogenous leukemia (AML) patients between 60 and 75 years irrespective of genetic risk: Report from the AML 2004 of the East German Study Group (OSHO).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e18501-e18501	2.2	4
73	The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. <i>Haematologica</i> , 2016 , 101, e482-e484	6.6	33
72	Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS). <i>British Journal of Haematology</i> , 2016 , 175, 917-924	4.5	6
71	JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib. <i>Annals of Hematology</i> , 2015 , 94, 1929-30	3	3
70	Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015 , 141, 2193-2039	4.9	5
69	The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. <i>Experimental Hematology and Oncology</i> , 2015 , 1, 21	7.8	32
68	International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. <i>Blood</i> , 2015 , 126, 291-9	2.2	693
67	Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2015 , 94, 1419-20	3	15
66	The Impact of Anemia on Overall Survival in Patients with Myelofibrosis Treated with Ruxolitinib: An Exploratory Analysis of the Comfort Studies. <i>Blood</i> , 2015 , 126, 1604-1604	2.2	2
65	Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis. <i>Blood</i> , 2015 , 126, 2799-2799	2.2	5
64	EXPAND: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Low Platelet Counts (50 \times 10 ⁹ /L to 99 \times 10 ⁹ /L) at Baseline. <i>Blood</i> , 2015 , 126, 2817-2817	2.2	5
63	Comprehensive Genomic Analysis Provides Further Evidence That Iron Overload Can Induce Genetic Instability in Myelodysplastic Syndromes. <i>Blood</i> , 2015 , 126, 2842-2842	2.2	7
62	Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results. <i>Blood</i> , 2015 , 126, 59-59	2.2	6
61	The Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) and Treatment with Ruxolitinib on Survival in Patients with Myelofibrosis. <i>Blood</i> , 2015 , 126, 2014-2014	2.2	
60	Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): First Data of the Interim Analysis of the DRKS00004519 Study of the East German Study Group (OSHO). <i>Blood</i> , 2015 , 126, 1346-1346	2.2	
59	Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies. <i>Blood</i> , 2015 , 126, 2517-2517	2.2	
58	Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients. <i>Leukemia</i> , 2014 , 28, 696-8	10.7	18
57	Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. <i>Bone Marrow Transplantation</i> , 2014 , 49, 179-84	4.4	83

56	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. <i>Haematologica</i> , 2014 , 99, 292-8	6.6	35
55	The role of hypomethylating agents in the treatment of elderly patients with AML. <i>Journal of Geriatric Oncology</i> , 2014 , 5, 89-105	3.6	42
54	Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial. <i>Blood</i> , 2014 , 124, 10-10	2.2	7
53	Complete Clinical, Histopathologic and Molecular Remission of Primary Myelofibrosis with Long-Term Treatment with the JAK1/2 Inhibitor Ruxolitinib. <i>Blood</i> , 2014 , 124, 1836-1836	2.2	4
52	Safety and Efficacy of Ruxolitinib in Patients with Low Platelets Enrolled in a Phase 3b Expanded-Access Study in Myelofibrosis (MF). <i>Blood</i> , 2014 , 124, 1859-1859	2.2	4
51	Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): Results of the Phase I of the DRKS00004519 Study. <i>Blood</i> , 2014 , 124, 2310-2310	2.2	1
50	Higher Leukemia Free Survival after Post-Induction Hematopoietic Cell Transplantation Compared to Consolidation Therapy in Patients >60 Years with Acute Myelogenous Leukemia (AML): Report from the AML 2004 East German Study Group (OSHO). <i>Blood</i> , 2014 , 124, 280-280	2.2	8
49	Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update. <i>Blood</i> , 2014 , 124, 3197-3197	2.2	2
48	Ruxolitinib Overcomes the Adverse Prognostic Effect of Anemia in Patients with Myelofibrosis (MF). <i>Blood</i> , 2014 , 124, 4583-4583	2.2	4
47	Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study. <i>Blood</i> , 2014 , 124, 621-621	2.2	7
46	Long Term Follow up of the AML97-Study for Patients with AML Older Than 60 Years: A Study of the East German Hematology and Oncology Study Group (OSHO). <i>Blood</i> , 2014 , 124, 3664-3664	2.2	
45	The Prognostic Impact of the Mutational Profile in Patients with Myelofibrosis in the Era of the JAK1/JAK2-Inhibitor Ruxolitinib. <i>Blood</i> , 2014 , 124, 1860-1860	2.2	
44	Reduced Intensity Conditioning Allogeneic Haematopoietic Stem Cell Transplantation - a Treatment Option in Elderly or Comorbid Patients with Acute Lymphatic Leukemia. <i>Blood</i> , 2014 , 124, 5945-5945	2.2	
43	Prognostic Factors for Overall Survival in Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 3666-3666	2.2	1
42	Subsequent Hematopoietic Stem Cell Transplantation in Belinostat-Treated Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL). <i>Blood</i> , 2014 , 124, 5438-5438	2.2	
41	Safety and Efficacy of Ruxolitinib Retreatment after Treatment Interruption in Patients Enrolled in an Open-Label, Multicenter, Expanded-Access Study in Myelofibrosis. <i>Blood</i> , 2014 , 124, 5567-5567	2.2	
40	Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013 , 139, 499-508	4.9	30
39	Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. <i>Blood</i> , 2013 , 122, 4047-53	2.2	328

38	Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013 , 139, 1937-46	4.9	31
37	Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. <i>British Journal of Haematology</i> , 2013 , 162, 229-39	4.5	60
36	Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077. <i>British Journal of Haematology</i> , 2013 , 162, 202-9	4.5	27
35	Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia. <i>OncoTargets and Therapy</i> , 2013 , 6, 741-8	4.4	4
34	Prognostic Significance Of EVI1 expression In Acute Myeloid Leukemia Patients With Intermediate and Adverse Cytogenetic Risk Undergoing Allogeneic Hematopoietic Cell Transplantation With Reduced-Intensity Conditioning. <i>Blood</i> , 2013 , 122, 3383-3383	2.2	1
33	The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT). <i>Blood</i> , 2013 , 122, 4070-4070	2.2	14
32	Prognostic Factors For Overall Survival In Elderly Patients With Relapsed Acute Myeloid Leukemia □ Retrospective Study On Behalf Of The East German Study Group For Hematology and Oncology (OSHO). <i>Blood</i> , 2013 , 122, 1409-1409	2.2	
31	Increasing The Dose Of AraC In Consolidation Therapy Does Not Lead To Higher Overall Survival Or Improved Relapse Incidence In Patients With AML Over The Age Of 60 Years. <i>Blood</i> , 2013 , 122, 2645-2645 ^{2,2}		
30	Outcome Of MDS and AML With MDS-Related Changes: Treatment Versus Prognostic Factors. <i>Blood</i> , 2013 , 122, 5223-5223	2.2	
29	JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. <i>New England Journal of Medicine</i> , 2012 , 366, 787-98	59.2	1232
28	Delayed processing of bone marrow samples reveals a prognostic pattern of NME mRNA expression in cytogenetically normal acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1561-8 ^{1,9}		4
27	Eisenchelat-Therapie mit Deferasirox: Therapiebeginn und Dosisoptimierung. <i>Tumor Diagnostik Und Therapie</i> , 2012 , 33, 29-33	0.1	1
26	Bcr-Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1569-76	1.9	8
25	Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). <i>Blood</i> , 2012 , 120, 167-167	2.2	10
24	Expand: a Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis and Baseline Platelet Counts Between 50 □09/L and 99 □09/L. <i>Blood</i> , 2012 , 120, 177-177	2.2	5
23	Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT). <i>Blood</i> , 2012 , 120, 802-802	2.2	7
22	Reductions in JAK2V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase III study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 6514-6514	2.2	3
21	Efficacy and Safety of Deferasirox in Patients with Transfusional Iron Overload After Allogeneic Hematopoietic Cell Transplantation: The C1CL670ADE02 Trial. <i>Blood</i> , 2012 , 120, 485-485	2.2	

20	Highly Elevated Serum Hcpidin in Patients with Acute Myeloid Leukemia prior to and after Allogeneic Hematopoietic Cell Transplantation: Does This Protect from Excessive Parenchymal Iron Loading?. <i>Advances in Hematology</i> , 2011 , 2011, 491058	1.5	13
19	Anemia and the Use of Erythropoietic-Stimulating Agents with Ruxolitinib in the COMFORT-II Study. <i>Blood</i> , 2011 , 118, 5147-5147	2.2	1
18	Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy. <i>Blood</i> , 2011 , 118, 795-795	2.2	
17	Efficacy and Safety Profile of Solvent/Detergent Plasma in the Treatment of Acute Thrombotic Thrombocytopenic Purpura: A Single-Center Experience. <i>Transfusion Medicine and Hemotherapy</i> , 2010 , 37, 13-19	4.2	13
16	The Oral Iron Chelator Deferasirox for Treatment of Transfusional Iron Overload After Allogeneic Hematopoietic Cell Transplantation Does Not Appear to Interfere with the Calcineurin Inhibitor Cyclosporin Trough Serum Levels. <i>Blood</i> , 2010 , 116, 1826-1826	2.2	2
15	The Ratio of Pre-Transplant Serum Ferritin to the Units of Blood Transfused and Not Serum Hcpidin Strongly Correlates with Outcome After Allogeneic Hematopoietic Cell Transplantation In Patients with AML and MDS.. <i>Blood</i> , 2010 , 116, 1307-1307	2.2	
14	High Levels of Nm23-H2 Protein Are a Specific and Invariable Feature of CML-CP Cells Due to Post Transcriptional Control Via a Bcr-Abl Dependent Pathway. <i>Blood</i> , 2010 , 116, 4461-4461	2.2	
13	Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.. <i>Blood</i> , 2009 , 114, 3286-3286	2.2	3
12	Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.. <i>Blood</i> , 2009 , 114, 3286-3286	2.2	6
11	Reduction of Relapse Incidence and Improvement of Leukemia Free Survival by Allogeneic Stem Cell Transplantation in Patients with AML and Normal Karyotype Irrespective of the FLT3-ITD Status.. <i>Blood</i> , 2009 , 114, 1612-1612	2.2	
10	Elevated Serum Hcpidin in Patients with AML Prior to and After Allogeneic Hematopoietic Cell Transplantation Does Not Correlate with Transfusional Body Iron, HFE Genotype or Graft Versus Host Disease and May Protect From Excessive Parenchymal Iron Loading.. <i>Blood</i> , 2009 , 114, 4047-4047	2.2	
9	Establishment of a Highly Sensitive Allele Specific Wild Type Blocker Polymerase Chain Reaction Followed by Pyrosequencing for Detection of the p.D816V Point Mutation.. <i>Blood</i> , 2009 , 114, 4975-4975 ^{2,2}		
8	Patients with Imatinib Resistance Harbour Low Level Mutations of the BCR-ABL Kinase Domain Predominantly in the CD34+ Cells.. <i>Blood</i> , 2009 , 114, 3267-3267	2.2	
7	Low Levels of Global (LINE) and CDH13 Methylation at Diagnosis and Rapid Clearance of Marrow Blasts Correlate with A Better Haematological Response to Azacitidine in Patients with Newly Diagnosed and Refractory/Relapsed AML Not Eligible for or Resistant to Chemotherapy: A Multi-Center Phase II Study for the European LeukemiaNet (ELN) Acute Myeloid Leukemia (AML) Study Group (AML0)	2.2	
6	Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.. <i>Blood</i> , 2009 , 114, 1115-1115	2.2	
5	Spontaneous remission of acute myeloid leukemia relapse after hematopoietic cell transplantation in a high-risk patient with 11q23/MLL abnormality. <i>Acta Haematologica</i> , 2008 , 119, 111-4	2.7	3
4	Hematopoietic Stem Cell Transplantation following Reduced Intensity Conditioning for High Risk Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2008 , 112, 4407-4407	2.2	
3	High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. <i>The Hematology Journal</i> , 2004 , 5, 55-60		100

- 2 High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. *Blood*, **2003**, 101, 2152-5 2.2 42
- 1 Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. *Blood*, **2003**, 101, 1941-9 201